NEJM Volume 363:397-398 July 22, 2010 Number 4
To the Editor: Aprepitant is the first commercially available drug of a new class of neurokinin-1–receptor antagonists for treating chemotherapy-induced nausea and vomiting. The dominant ligand for the neurokinin-1 receptor is substance P.1,2 An increase in the number of neurokinin-1 receptors on keratinocytes has been found in patients with chronic pruritus. A recent report described an improvement in pruritus related to the Sézary syndrome after aprepitant administration.3
Weblink here
